STK11 and cancer: In addition, since phenformin may serve as an AMPK activator in cells with wild type LKB1 [16, 21, 24], and negatively regulates mTOR activity, it is also reasonable to combine selumetinib with phenformin in cancer cells with wild type LKB1 (Supplementary Figure 4).